Table 3.
Demographic and baseline characteristics of the trial subjects.
Placebo (n=25) | Chromium Picolinate (n=25) | Chromium Dinicocysteinate (n=24) | |
---|---|---|---|
Age (years) | 48.64±1.99 | 51.12±2.03 | 48.79±1.82 |
Gender: male/female (%) | 2/23 (8.70%) | 7/18 (38.89%) | 8/16 (50%) |
Weight (kg) | 100.47±5.52 | 103.94±6.39 | 104.31±6.93 |
BMI | 38.00±1.71 | 35.44±2.06 | 36.85±2.20 |
Fasting Glucose (mg/dL) | 142.4±12.32 | 128.88±8.78 | 131.95±9.61 |
HbA1C (%) | 7.84±0.34 | 7.54±0.32 | 7.65±0.35 |
Where applicable, values are expressed as Mean ± SEM. No significant difference was observed among the groups.